Indication intelligence, analysis and sector perception

RegMed Investors (RMi) Research Note:CRISPR Therapeutics (CRSP) announces Registered Direct Offering (RDO) of $280 M priced at $71.50 per share

February 21, 2024 12:17pm

CRSP trading up at $3.73 at +4.73% at $82.45 <so far>

CRSP reported its first profit in 10 quarters on Wednesday,

The financing is expected to close on or about February 27, 2024, subject to customary closing conditions.

Has entered into an investment agreement for the sale of approximately $280 million of its common shares to a select group of institutional investors in a registered direct offering, at a price per share of $71.50, representing a premium of greater than 10% to CRISPR Therapeutics’ 30-day volume-weighted average price.

The Bottom Line: after a net income for Q4 /23 - why not ... as FY&23 rang in a net loss of $136,050 M or -$1.94

Q4/23 revenue also topped projections at $201.2 million.

Now that CRSP and Vertex (VRTX) are working to commercialize Casgevy, Crispr's earlier-stage pipeline efforts more closely watched. CEO Kulkarni said Crispr began testing two treatments for cardiovascular diseases in people last year.

CRSP is also testing cancer treatments "which have the potential to be best-in-class cell therapies for the treatment of both liquid and solid tumors," he said in a written statement. He sees the next 12 to 18 months as being particularly "catalyst-rich" for the company. <IBD>

Debt: $241.59 M

52-week range: $90.18 and a low of $37.55

Shares outstanding: 83.36 M

Float: 78.42 M shares

Short ratio: 7.89%

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.